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1. Introduction 
Although, during the past four decades, a great 
deal of work has been focused on factors known to 
regulate human pregnancy and parturition, the com- 
plex mechanisms involved in these physiological 
events are still not completely known. Since 1930, 
when Fekete [l] observed that the plasma from 
pregnant women inactivated the oxytocic principle 
from the posterior pituitary gland, the enzyme oxy- 
tocinase causing this inactivation has been assigned 
an important role, in regulating the blood oxytocin 
during pregnancy. The present review will provide a 
basis for discussion of the possible physiological sig- 
nificance of this oxytocin-oxytocinase equilibrium 
for the initiation of labour at the end of pregnancy. 
In fig. 1, the inactivation of oxytocin caused by 
oxytocinase is included as one of the processes, 
which regulate the free circulating amount of oxy- 
tocin in blood, besides the uptake and metabolism of 
the hormone in the liver, kidneys and possibly also 
in other tissues. Indicated as an uncertain mecha- 
nism is the possible complex formation between oxy- 
tocin and blood proteins. It is apparent from this 
scheme, that the relative physiological importance of 
oxytocinase will, of course, depend on the concentra- 
tion of the enzyme, the presence of enzyme inhibi- 
tors or activators in the blood, the inactivation rate, 
i.e. the properties of oxytocinase, as well as the time 
needed to transport the oxytocin from the pituitary 
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Fig. 1. Summary of some mechanisms regulating the free 
concentration of oxytocin in blood of pregnant women. 
gland to the target organ, i.e. the half-life (rt) of oxy- 
tocin in the blood, and the extent of the up ake and 
inactivation of oxytocin, which takes place in the 
liver, kidneys and other tissues. 
2. Oxytocinase 
Oxytocinase reaches its highest concentration in 
the blood at term [2-51. No decline in the enzyme 
activity has been observed immediately before deli- 
very, thus giving no support to the theory that a 
diminished synthesis of oxytocinase initiates labour. 
The individual variations are, however, large. Even if 
certain pathological conditions are known to increase 
or decrease the blood oxytocinase [3,4,6,7,8], the 
differences from the normal values will be too small 
to yield statistically significant discrepancies. This 
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means, unfortunately, that the value of oxytocinase 
estimations as a diagnostic tool has, hitherto, been 
limited. However, in cases of multiple pregnancy, the 1) 2) 
oxytocinase concentration has been proved to be 
higher than that in single pregnancies [3,9]. 
In view of its high oxytocinase content, retro- 
placental blood serves as a convenient starting 
material for preparation of the enzyme and essen- 
tially homogeneous preparations have been obtained 
after ethanol fractionation and chromatography on 
hydroxylapatite, Sephadex G-200 or ion exchangers 
[lo-141 . Purified oxytocinase gives rise to two bands 
in both polyacrylamide-gel and vertical starch-gel 
electrophoresis [ 15-2 l] . The two bands have the 
same ability to degrade oxytocin, lysine-vasopressin 
and L-cystine-di-/3-naphthylamide [ 181 and form a 
reversible pH-dependent equilibrium with each other 
in the pH range 8.2 to 9.6 [ 191. The two bands re- 
present two different conformations of the enzyme, 
most probably obtained by different spatial arrange- 
ment of the peptide chains around the sia.lic acid re- 
sidues, as treatment of the enzyme with neuraminidase 
yields a preparation, which gives only one band in 
starch-gel and polyacrylamide-gel electrophoresis [ 13, 
19,221. In some cases, sera from pregnant women 
have been shown to contain also a third new peptidase 
band [23-251, the properties of which, however, are 
not yet known. 
Tuppy et al. initially showed that oxytocinase is a 
glycoprotein, containing sialic acid [22]. Additionally, 
we have found in preliminary experiments neutral 
hexoses and amino sugars, but no 2-deoxy sugars. The 
total carbohydrate content in oxytocinase has been 
calculated to be around 40% Its molecular weight, 
estimated on the basis of the sedimentation constant 
and the Stokes’ radius obtained from gel-filtration 
data, is 325,000 [26]. 
The enzyme specificity of oxytocinase is presently 
well documented, as far as synthetic amino acid 
derivatives [22,27], cysteine peptides [ 11,28-301, 
other dipeptides and oligopeptides [2,31-341 are 
concerned. The enzyme has a broad specificity, hy- 
drolyzing all natural peptide bonds, except imido- 
peptide bonds, from the N-terminal end, when the 
N-terminal amino acid has a free amino group and is 
of L form. This property gives oxytocinase the posi- 
tion as the only single enzyme known to hydrolyze 
N-terminally situated half-cystinyl bonds, which ex- 
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Fig. 2. Degradation of oxytocin with oxytocinase. 
plains the synonymous use of the term “cystine 
aminopeptidase”(CAP) for oxytocinase. 
Because of its broad specificity, oxytocinase 
causes complete degradation of oligopeptides into 
amino acids and, if proline is present, peptides with 
proline next to the N-terminus [32-341. This is 
illustrated in fig. 2, showing degradation of oxytocin 
with a pure oxytocinase preparation [33]. However, 
large polypeptides such as insulin, or proteins such as 
human serum albumin, are only inappreciably de- 
graded [34] . The size of a peptide showing the highest 
affinity between peptide and enzyme and the highest 
reaction velocity remain to be investigated. 
3. Oxytocin 
To allow any conclusions to be drawn about the 
physiological significance of oxytocinase in blood, 
the distribution rate of oxytocin from blood, i.e. the 
half-life (D), and the relative uptake in the target 
organ(s) compared with the uptake and storage in 
other tissues, have to be known. Ginsburg has earlier 
compiled in a review [35] the facts known up to 
1963 in this field. 
The clearance from blood of oxytocin, vasopressin 
and some of their synthetic analogues has been shown 
to proceed rapidly, the @ being estimated as about 
100 set in the rat [35,34,4-g min for arginine-vaso- 
pressin in males [37,38], and 1.2-4 min for oxytocin 
in pregnant women [39]. In the great majority of 
cases, the estimations were based on the biological 
activity remaining after intravenous single doses, or 
after interruption of steady-state infusions. In these 
situations, however, large “pharmacological” doses 
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were given, making the physiological interpretation un- 
certain. Since radioactively labeled hormones with 
high specific radioactivity are now available [40], it 
has been possible to decrease the doses used substan- 
tially (unfortunately not yet to the “physiological” 
level), and to make more extensive studies under dif- 
ferent hormonal conditions in animals and in human 
beings. 
The half-life of oxytocin in blood seems to be in- 
fluenced by other hormones. This has been found to 
be so in the rat, since pregnancy causes a decrease in 
f; of both oxytocin and lysine-vasopressin (from 97 
and 113 set to 79 and 99 set, respectively [36]). The 
values from the non-pregnant rats are in good accord 
with those obtained with higher doses of non-radio- 
active hormones, which may imply that the dose is of 
secondary importance. Moreover, it is to be noted 
that oophorectomy causes an increased clearance from 
the blood, and that oestrogen treatment of these rats 
partly restores the TV to non-pregnant values [36]. 
Clearance studies!of oxytocin in pregnant and 
non-pregnant women are scarce, owing to the diffi- 
culties of estimating small amounts of oxytocin. The 
values of Gonzales-Panizza et al. (f$ = 1.2-4 min) 
were obtained from 4 patients with dead foetuses 
near the calculated term, or post parfum after macro- 
infusions of 8-18 IU per min [39]. Our own studies 
[42] were performed on about 50 non-pregnant and 
pregnant volunteers. The non-pregnant women con- 
sisted both of those menstruating normally, who were 
classified according to the day of their menstruating 
cycle, and of those taking contraceptive tablets with 
gestagenic and oestrogenic hormones. The pregnant 
women were hospitalized for legal abortion, either 
by abrasio (pregnancy 5 12 weeks) or by intra-amnio 
tic instillation of hypertonic glucose (pregnancy 14-20 
weeks). In the latter group, t: was also determined 
within 24 hr of the abortion,‘in addition to the esti- 
mation made in all patients just before the instillation 
or operation. The results are summarized in table 1. 
The values in the non-pregnant group taking con- 
traceptive tablets are significantly lower than those in 
women in the oestrogen-dominated part of the cycle, 
which is in accord with the results in the rats. Among 
the pregnant women, a decrease in $ was seen in all 
cases after abortion, and, generally, the change was 
very evident. The decrease in TV was not followed by 
a similar marked increase in thg blood oxytocinase 
concentration (CAP). Although a slight increase was 
seen in many patients, this increase cannot be con- 
sidered as significant, as tissue injuries are often fol- 
lowed by an increase of the peptidase activity in blood. 
Table 1 
Half-life of oxytocin in blood of non-pregnant and pregnant women. 
Group of women Hormonal stage tr* 
A 
Non-pregnant Proliferative phase 272 f 14.2 (14) 
Secretory phase 
(18th-22nd day) 
221 + 14.9 ( 5) 
On oral contraceptives 
(gestagens + oestrogens) 
199 ?s 9.8 (10) 
Pregnant 5 12 weeks pregnancy 
14- 17 weeks pregnancy 
prior to abortion 
after abortion 
18-20 weeks pregnancy 
prior to abortion 
after abortion 
178 + 13.9 ( 6) 
295 + 47.2 ( 6) 
229 + 21.5 ( 6) 
282 f 21.3 ( 6) 
181 f 14.0 ( 6) 
* Expressed as arithmetic mean + standard deviation followed by the number of observations in parentheses. 
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The increased CAP activity might then be due to 
damage to the placenta, which contains large amounts 
of oxytocinase [8] . The markedly decreased tl after 
abortion might instead have been due to a chaige in 
the ratio between gestagenic and oestrogenic hor- 
mones, but it is more probable that more complex 
unknown regulatory mechanisms are involved in the 
distribution of oxytocin. This is further illustrated 
early in pregnancy (before the 12th week), when 
oxytocin is distributed more rapidly than later (in the 
14th-20th weeks), despite a smaller myometrium 
and placenta. Nevertheless, the studies on the half- 
life of oxytocin have revealed that gestagens increase 
the distribution rate, and oestrogens decrease it. It 
remains to be shown whether these results are due 
to effects on unspecific organs such as the liver and 
kidneys or on the specific target organs. 
Slight effects on the liver and kidneys can be ex- 
pected to result in marked changes in the tl in blood. 
Both vasopressin and oxytocin are mainly &en up in 
these organs [35,4 1,43,44] . By direct measurement 
of the radioactivity content in different tissues in the 
rat after intravenous injection of tritiated oxytocin, 
previous evidence has been quantitatively confirmed 
[45,46]. Twenty to thirty percent of the total amount 
of oxytocin injected was taken up in the liver and 
kidneys 60 set after injection, which corresponds to 
more than 50% of the amount which has left the cir- 
culation [46], as f+ is around 100 sec. In women, 
40-50% of the injected radioactivity was recovered 
in the urine within 3 hr [42]. 
4. Conclusions 
Oxytocin is of fundamental importance in regu- 
lating uterine muscle activity during delivery. Oxy- 
tocinase has also been ascribed a role as the specific 
oxytocin-inactivating component of the blood. Con- 
vincing proof exists that oxytocinase has the ability 
to degrade the hormone enzymatically, but, at present, 
the physiological significance of the inactivation 
mechanism is doubtful. Some facts about oxytocin 
and oxytocinase are known from late stages of the 
pregnancy, or from women in labour, but most know- 
ledge has been gained from studies in animals, in non- 
pregnant women or in women in early pregnancy. 
Certainly, hormonal and other regulatory conditions 
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are changed up to delivery, but if the results are as- 
sumed to be valid during delivery as well, the following 
short summary can be made of the apparently most im- 
portant factors arguing for and against oxytocinase as 
an important regulating enzyme, at the end of pregnancy. 
Against the importance of oxytocinase 
(1) The concentration of oxytocin in blood is very 
low (< 1 /.mnit/ml), and even if the release of oxytocin 
from the pituitary is increased during labour [47-491 , 
the low concentration decreases the chances of oxy- 
tocin being degraded because of competitive inhibition 
of other peptides. 
(2) The half-life of oxytocin in blood is short. 
(3) Oxytocin is taken up extensively in the liver 
and kidneys, and probably almost completely inacti- 
vated there. This means that the relative importance 
of inactivation in the blood is small. 
(4) In view of the broad specificity of oxytocinase, 
other peptides are also attacked by the enzyme. How- 
ever, the relative affinity of oxytocin to the enzyme 
and the inactivation rate in comparison to that of other 
peptides have not hitherto been established. 
(5) The transport form of oxytocin is not yet 
known. There still exists the possibility, which is not, 
however, probable as judged by the short t! , that oxy- 
tocin is bound to a protein in blood. This c&r take 
place in such a way that the inactivation is either ex- 
cluded (as for instance, when the o-amino group is 
bound to neurophysin in the pituitary gland) or de- 
creased. 
For the importance of oxytocinase 
(1) Oxytocinase reaches its highest concentration 
at term. However, the blood level is still low, about 
4mg/l[13]. 
(2) In pure incubation mixtures, oxytocin is 
readily degraded by oxytocinase. 
Uncertain factors are, among others, the oestrogens 
and gestagens, which reach high concentrations near 
term, and which have been shown to considerably 
affect the clearance rate of oxytocin from blood. The 
mechanism of their action, however, still remains un- 
clear. Another very important factor, which still is 
unknown, is the threshold dose of oxytocin for re- 
sponse in the target organ and the effect of small varia- 
tions around this dose. Knowledge in these matters 
will simplify the estimation of the importance of oxy- 
tocinase during late pregnancy. 
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To sum up, the physiological importance of oxy- 
tocinase in blood does not at present appear con- 
vincing. It therefore seems reasonable to speculate 
that the presence of the enzyme in blood has no func- 
tional explanation, but merely reflects the increased 
metabolic activity of the placenta, from which the 
enzyme leaks out into the circulation. The latter hypo- 
thesis is also supported by the results of Riad [50] and 
Branda et al. [Sl] , who found that oxytocinase was 
released into the blood during labour. 
References 
111 
121 
I31 
141 
151 
[61 
[71 
181 
[91 
K.von Fekete, Endokrinologie 7 (1930) 364. 
H.Tuppy, in: Oxytocin, eds. R.Caldeyro-Barcia nd 
H.Heller (Pergamon Press, Oxford, 1961) p. 315. 
S.Melander, Acta Endocrinol. 48 suppl. 96 (1965). 
C.Babuna and E.Yenen, Am. I. Obst. GynecoL 94 
(1966) 863. 
R.Klimek. Gynaecologia 163 (1967) 48. 
S.E.Dicker and G.A.WhyIey, J. Obst. Gynaecol. 66 
(1959) 605. 
P.Fylling, Acta Obst. Gynecol. Stand. 42 (1963) 227. 
G.Ryden, Acta Obst. Gynecol. Stand. 45 suppl. 3 (1966). 
S.D.Ichaliotis and Th.C.Lambrinopoulos, Obst. Gyne- 
col. 25 (1965) 270. 
[lo] H.Tuppy and E.Wintersberger, Monatsh. Chem. 91 
(1960) 1001. 
[ 1 l] M.&ha?, Z.Berankova, I.Rychlik and F.Sorm, COB. Czech. 
Chem. Commun. 26 (196 1) 2632. 
[ 121 LSjoholm. L.Yman and F.Sandberg, Acta Pharm. 
Suecica 2 (1965) 261. 
[ 131 LSjbholm and L.Yman, Acta Pharm. Suecica 3 (1966) 
377. 
[ 141 T.Barth, V.PliSka, LRychlik and F.‘Sorm, Coll. Czech. 
Chem. Commun. 32 (1967) 2327. 
[ 151 E.Wintersberger and H.Tuppy, Monatsh. Chem. 91 
(1960) 406. 
[ 161 E.W.Page, M.A.Titus, G.Mohun and M.B.Glendening, 
Am. J. Obst. Gynecol. 82 (1961) 1090. 
[ 171 J.F.Afonso and R.R.de Alvarez, Am. J. Obst. Gynecol. 
89 (1964) 204. 
[ 181 M.B.Glendening, M.A.Titus, S.A.Schroeder, G.Mohun 
and E.W.Page, Am. J. Obst. Gynecol. 92 (1965) 8 14. 
[ 191 LSjoholm and L.Yman, Acta Pharm. Suecica 3 (1966) 
389. 
[ 201 H.Kleiner and E.Schram, Clin. Chim. Acta 14 (1966) 
377. 
[211 
[221 
1231 
v41 
v51 
1261 
1271 
[281 
[291 
[301 
1311 
1321 
[331 
[341 
I351 
[361 
[371 
[381 
1391 
[401 
[411 
[421 
H.Kleiner and G.Graff, Compt. Rend. Seanc. Sot. BioL 
160 (1966) 714. 
H.Tuppy, U.Wiesbauer and E.Wintersberger, Monatsh. 
Chem. 94 (1963) 321. 
L.Beckman and M.Grivea, Acta Paediat. Stand. 54 
(1965) 578. 
L.Beckman, G.BjGrling and C.Christodoulou, Acta Genet. 
16 (1966) 122. 
J.G.Scandalios, J. Hered. 58 (1967) 153. 
L.Yman and I.Sjoholm, Acta Pharm. Suecica 4 (1967) 13. 
H.Tuppy, U.Wiesbauer and E.Wintersberger, Z. PhysioL 
Chem. 329 (1962) 278. 
Z.Berankovi, I.Rychlik and F.Sorm, ColL Czech. Chem. 
Commun. 25 (1960) 2575. 
Z.Berankova, I.Rychlik and F.Sorm, Coll. Czech. Chem. 
Commun. 26 (1961) 1708. 
Z.Be&kovl and F.Sorm, ColL Czech. Chem. Commun. 
26 (1961) 2557. 
I.SjBholm, Acta Chem. Stand. 18 (1964) 889. 
I.Sjoholm and L.Yman, Acta Pharm. Suecica 4 (1967) 
65. 
I.Sjoholm, Acta Pharm. Suecica 4 (1967) 81. 
I.Sjoholm, in preparation. 
M.Ginsburg, in: Oxytocin, Vasopressin and their 
Structural Analogues, ed. J.Rudinger (Pergamon Press, 
Oxford, 1964) p. 87. 
I.Sjoholm and G.Ryden, Acta Pharm. Suecica 4 (1967) 
23. 
L.Silver, I.L.Schwartz, C.T.O.Fong, A.F.Debons and 
L.K.Dahl, J. Appl. Physiol. 16 (1961) 1097. 
J,W.Czaczkes, C.R.Kleeman and M.Koenig, J. Clin. In- 
vest. 43 (1964) 1625. 
V.H.Gonzalez-Panizza, YSica-Blanc0 and C.MBndez- 
Bauer, in: Oxytocin, eds. R.CaldeyroBarcia and 
H.Heller (Pergamon Press, Oxford, 1961) p. 347. 
I.Sjdholm and L.Carlsson, J. LabeIled Comds 3 (1967) 3. 
H.D.Lauson, Am. J. Med. 42 (1967) 713. 
G.Ryden and I.Sjoholm, Acta Endocrinol. (1969), 
in press. 
[43] M.Ginsburg and M.W.Smith, Brit. J. Pharmacol. 14 
(1959) 327. 
[ 441 N.A.Thorn and M.W.Smith, Acta Endocrinol. 4 (1965) 
388. 
[45] J.P.Aroskar, W.Y.Chan, J.E.Stouffer, C.H.Schneider, 
V.V.S.Murti and V.du Vigneaud, EndrocrinoL 74 (1964) 
226. 
[46] I.Sjoholm and G.Ryden, Acta Endocrinol. (1969), in 
press. 
[47] J.A.Coch, J.Brovetto, H.M.Cabot, C.Fielitz and R.Cal- 
deyro-Barcia, Am. J. Obst. Gynecol. 91 (1965) 10. 
[48] C.G.van Dongen and R.L.Hays, J. Reprod. Fert. 11 
(1966) 317. 
[49] J.A.Coch, C.Fielitz, J.Brovetto, H.M.Cabot, H.Coda 
and A.Fraga, J. Endocrinol. 40 (1968) 137. 
[SO] A.M.Riad, J. Obst. Gynaecol. 73 (1966) 977. 
1511 L.A.Branda, B.M.Ferrier, G.Archimaut, E.A.Marchelli 
and B.Rucanski, Science 160 (1968) 81. 
139 
